Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Voss

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Vaccine|August 17, 2006
Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaquesV Ann Stewart, Douglas S Walsh, Shannon M McGrath, et al.
Plos One|April 10, 2015
Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaquesClarisse Lorin, Yannick Vanloubbeeck, Sébastien Baudart, et al.
Vaccine|August 24, 2010
Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant SystemsIsabel Leroux-Roels, Marguerite Koutsoukos, Frédéric Clement, et al.
Vaccine|February 6, 2026
Use cases for pan-sarbecovirus vaccines: a workshop reportEmily A Smith, Melissa Malhame, Stefano Malvolti, et al.
Vaccine|November 20, 2021
Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12-13 February 2020Gerald Voss, Jeanne-Marie Jacquet, Nadia Tornieporth, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2007
Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunizationPeng Fei Zhang, Fatim Cham, Ming Dong, et al.
Journal of Virology|May 14, 2004
Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodiesNancy L Haigwood, David C Montefiori, William F Sutton, et al.
Vaccine|October 23, 2013
Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled studyThomas Harrer, Andreas Plettenberg, Keikawus Arastéh, et al.
Plos Pathogens|October 4, 2008
B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4Mattias N E Forsell, Barna Dey, Andreas Mörner, et al.
The American Journal of Tropical Medicine and Hygiene|July 14, 2006
Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western KenyaJosé A Stoute, D Gray Heppner, Carl J Mason, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Vaccine|August 17, 2006
Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaquesV Ann Stewart, Douglas S Walsh, Shannon M McGrath, et al.
Plos One|April 10, 2015
Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaquesClarisse Lorin, Yannick Vanloubbeeck, Sébastien Baudart, et al.
Vaccine|August 24, 2010
Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant SystemsIsabel Leroux-Roels, Marguerite Koutsoukos, Frédéric Clement, et al.
Vaccine|February 6, 2026
Use cases for pan-sarbecovirus vaccines: a workshop reportEmily A Smith, Melissa Malhame, Stefano Malvolti, et al.
Vaccine|November 20, 2021
Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12-13 February 2020Gerald Voss, Jeanne-Marie Jacquet, Nadia Tornieporth, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2007
Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunizationPeng Fei Zhang, Fatim Cham, Ming Dong, et al.
Journal of Virology|May 14, 2004
Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodiesNancy L Haigwood, David C Montefiori, William F Sutton, et al.
Vaccine|October 23, 2013
Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled studyThomas Harrer, Andreas Plettenberg, Keikawus Arastéh, et al.
Plos Pathogens|October 4, 2008
B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4Mattias N E Forsell, Barna Dey, Andreas Mörner, et al.
The American Journal of Tropical Medicine and Hygiene|July 14, 2006
Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western KenyaJosé A Stoute, D Gray Heppner, Carl J Mason, et al.
Pageof 5